Ϫ cotransporter (NKCC2)-mediated NaCl reabsorption in the thick ascending limb (TAL) is stimulated by AVP via V2 receptor/PKA/cAMP signaling. This process is antagonized by locally produced eicosanoids such as 20-HETE or prostaglandin E2, which are synthesized in a phospholipase A2-dependent reaction cascade. Using microarray-based gene expression analysis, we found evidence for an AVP-dependent downregulation of the calcium-independent isoform of PLA2, iPLA2␤, in the outer medulla of rats. In the present study, we therefore examined the contribution of iPLA2␤ to NKCC2 regulation. Immunoreactive iPLA2␤ protein was detected in cultured mTAL cells as well as in the entire TAL of rodents and humans with the exception of the macula densa. Administration of the V2 receptorselective agonist desmopressin (5 ng/h; 3 days) to AVP-deficient diabetes insipidus rats increased outer medullary phosphorylated NKCC2 (pNKCC2) levels more than twofold in association with a marked reduction in iPLA2␤ abundance (Ϫ65%; P Ͻ 0.05), thus confirming microarray results. Inhibition of iPLA2␤ in SpragueDawley rats with FKGK 11 (0.5 M) or in mTAL cells with FKGK 11 (10 M) or (S)-bromoenol lactone (5 M) for 1 h markedly increased pNKCC2 levels without affecting total NKCC2 expression. Collectively, these data indicate that iPLA2␤ acts as an inhibitory modulator of NKCC2 activity and suggest that downregulation of iPLA2␤ may be a relevant step in AVP-mediated urine concentration. thick ascending limb; eicosanoids; vasopressin STIMULATION OF THICK ASCENDING limb (TAL) transport by AVP is an established element for the normal function of the urine concentrating mechanism. In the TAL, AVP stimulates transepithelial NaCl transport by increasing the abundance, phosphorylation, and surface expression of the type 2 Na
STIMULATION OF THICK ASCENDING limb (TAL) transport by AVP is an established element for the normal function of the urine concentrating mechanism. In the TAL, AVP stimulates transepithelial NaCl transport by increasing the abundance, phosphorylation, and surface expression of the type 2 Na
Ϫ cotransporter (NKCC2). This effect is mediated by the AVP V2 receptor and involves an increase in intracellular cAMP concentration leading to subsequent activation of protein kinase A and probably also other protein kinases (2, 20) . The activation of NKCC2 is counteracted by locally produced arachidonic acid derivatives such as 20-HETE, 14,15-epoxyeicosatrienoic acid (14,15-EET), or PGE 2 (2, 10, 18) . Impairment of this response may cause Na ϩ retention and hypertension (19) .
The common, rate-limiting step in the biosynthesis of all eicosanoids is the release of arachidonic acid from membrane glycerophospholipids by PLA 2 isoenzymes (7). At present, over 30 different enzymes with PLA 2 activity have been cloned and grouped according to sequence homologies or biochemical properties (30, 37) . Characteristically, these enzymes differ with respect to their dependence on ionized calcium. As an ample source of eicosanoids, the kidney expresses both calcium-dependent and calcium-independent PLA 2 activity (23) , and the calcium-dependent PLA 2 group IVA has been shown to be involved in the regulation of the renal urine concentrating mechanism (11) . Currently, six proteins with calcium-independent PLA 2 activity (iPLA 2 ) have been identified and designated as iPLA 2 group VIA to VIF (37) . The isoforms iPLA 2 -VIA and -iPLA 2 -VIB, more recently termed iPLA 2 ␤ and iPLA 2 ␥, respectively, have been studied in detail (1) . They were shown to be activated by ATP and inhibited by bromoenol lactone (BEL), and their functions included phospholipid remodeling, regulation of cell proliferation and apoptosis, activation of storage-operated calcium channels, regulation of vascular tone, and the release of arachidonic acid from membrane phospholipids (1) . Apart from data on a calcium-independent PLA 2 isoform mediating the inhibitory effects of dopamine on TAL transport (16) , little is currently known about the distribution and effects of renal iPLA 2 isoenzymes.
Microarray studies from our group suggested that outer medullary iPLA 2 ␤ mRNA levels were reduced after treatment with the V2 receptor-selective agonist 1-desamino-8-D-Arg vasopressin (desmopressin; dDAVP; 5 ng/h; 3 days) whereas other iPLA 2 isoforms were not affected. This prompted us to study the role of iPLA 2 ␤ in TAL in more detail. We have shown that 1) iPLA 2 ␤ is expressed in the TAL of mouse, rat, and human kidneys; 2) iPLA 2 ␤ expression in the outer medulla is inhibited by chronic exposure to the AVP V2 receptor agonist dDAVP; and 3) pharmacological inhibition of iPLA 2 ␤ activity increases the abundance of phosphorylated NKCC2 in cultured medullary TAL cells (mTAL cells) and rat outer medulla. Our results suggest that iPLA 2 ␤ is an effective inhibitory regulator of TAL transport activity. Downregulation of iPLA 2 ␤ by AVP may therefore be essential for sustained activation of the urine concentrating mechanism.
MATERIALS AND METHODS
Animal studies and tissue preservation. Adult male Sprague-Dawley (SD) rats (n ϭ 6), Brattleboro rats with a hereditary central diabetes insipidus (40) (DI; originally obtained from Harlan Winkelmann, Borchen, Germany; n ϭ 16), and C57/BL6 mice (n ϭ 6) were bred in the local animal facility (Charité, Berlin, Germany) and kept on a standard diet and tap water. All animal studies were performed according to National Institutes of Health guidelines and were approved by the Berlin council on animal care (permission numbers G006-02/05 and G0285/10). For microarray studies, young (8 wk) adult male Brattleboro rats were randomly divided into two groups (n ϭ 3/group) and treated for 3 days with either dDAVP (5 ng/h; SigmaAldrich, Hamburg, Germany) or vehicle via an osmotic minipump (Alzet minipump, model 2001, Charles River, Sulzfeld, Germany). At the end of the treatment period, the animals were euthanized and their kidneys were removed. The outer medulla was isolated and used for cDNA generation and subsequent microarray analysis. For localization studies, SD rats and mice (n ϭ 3) were anesthetized by isoflurane (Abbott, Wiesbaden, Germany) inhalation followed by an injection of pentobarbital sodium (0.06 mg/g body wt ip, Fagron, Barsbüttel, Germany). The abdominal cavity was opened, and kidneys were fixed with 3% paraformaldehyde (PFA; Merck, Darmstadt, Germany) in PBS via retrograde perfusion of the abdominal aorta. After perfusion, kidneys were carefully removed and processed for paraffin embedding or cryostat sectioning using routine methodology. Additional animals (n ϭ 3) were euthanized after deep isoflurane anesthesia; kidneys were removed and processed for protein biochemistry or cDNA generation. To determine the intrarenal distribution of iPLA 2␤ variants, different zones of rat kidneys were separated using sterile razor blades. Human kidney samples (n ϭ 3) were derived from tumor nephrectomy specimens after written consent of the patients. Samples from the healthy parts of the kidneys were fixed by immersion in 3% PFA in PBS and processed for immunohistochemistry (31) . The effects of chronic AVP treatment on renal iPLA 2␤ expression was verified in additional male Brattleboro rats (n ϭ 8/group). Treatment with dDAVP was performed as described above. At the end of the treatment period, animals (4/group) were euthanized and their kidneys were removed. The outer medulla was isolated and used for cDNA generation or protein biochemistry. The remaining animals were perfusion fixed and processed for histological studies as described above. To test the relevance of iPLA 2␤ for the regulation of NKCC2 in vivo, we employed the novel iPLA2␤-specific inhibitor 1,1,1,2,2-pentafluoro-7-phenyl-3-heptanone (FKGK 11; Cayman Chemical, Tallin, Estonia) (5).. Young male SD rats (n ϭ 10) were randomly divided into two groups. FKGK 11 was administered by intraperitoneal injection of 250 l of a 2 mM solution of FKGK 11 dissolved in PBS supplemented with 5% Tween 80 (Sigma-Aldrich) as previously described (27) . Control animals were injected with vehicle. After 1 h, animals were perfusion fixed and processed for immunoperoxidase staining as detailed above.
Microarray studies. Gene expression profiling was performed in the microarray facility of the Zentrum für Medizinische Forschung of the University of Mannheim (Mannheim, Germany). Total RNA was isolated from the outer medulla of dDAVP-and vehicle-treated Brattleboro rats using a Qiagen RNeasy minikit following the manufacturer's instructions (Qiagen, Hilden, Germany). cDNA and cRNA were prepared according to the Affymetrix standard labeling protocol. Hybridization to Affymetrix rat genome 230 2.0 arrays was performed with GeneChip Hybridization oven 640. Chips were subsequently dyed in GeneChip Fluidics Station 450 and thereafter scanned with GeneChip Scanner 3000. All equipment was from Affymetrix (Affymetrix, High Wycombe, UK). Data were analyzed using commercial software (JMP Genomics version 4, SAS, Cary, NC). Custom CDF Version 9 with Unigene-based gene definitions was used to annotate the arrays (http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/CDF_download_v9.asp). The raw fluores- cence intensity values were normalized by applying quantile normalization. Raw and normalized data were deposited in the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/; GEO accession number: GSE34225). To elucidate the effects of AVP treatment on PLA 2 isoenzymes expressed in the TAL, we combined a comprehensive list of mammalian enzymes with PLA2 activity (30) with information from a published database on the transcriptome of microdissected mTALs (http://dir.nhlbi.nih.gov/papers/lkem/mtaltr/ Default.aspx) (43) . The effect of AVP treatment on the identified enzymes was determined by microarray.
Cell culture experiments. For cell culture experiments, we used a rat medullary TAL cell line generated by Eng et al. (12) . Cells were grown to confluence in renal epithelial cell growth medium (PromoCell, Heidelberg, Germany) and processed for immunofluorescence staining, cDNA generation, or protein biochemistry as previously described (31, 41) . To study the effects of iPLA 2 inhibition on NKCC2 phosphorylation and protein abundance, cells were treated with BEL (5 M; Sigma-Aldrich), (R)-BEL, and (S)-BEL (5 M; Cayman Chemical) for 1 h. The concentration for BEL treatment has been previously shown to inhibit rat iPLA 2␤ and -␥ by 100 and 80%, respectively (21) . In addition, cells were treated for 1 h with either the novel iPLA2␤ inhibitor FKGK 11 (10 M; Cayman Chemical), with the nonspecific PLA2 inhibitor methyl arachidonyl fluoro-phosphate (MAFP; 100 M; Cayman Chemical), or the inhibitor of phosphatidate phosphohydrolase (PAPH) propranolol (250 M; Sigma Aldrich) (3, 5, 25) . After treatment, cells were either collected for protein biochemistry or processed for immunofluorescence as previously described (31, 41) .
Conventional and real-time PCR. Total mRNA was isolated as described above. After digestion of genomic DNA by DNase 1 treatment (Qiagen), cDNA was generated by RT using an Applied Biosystems cDNA synthesis kit (Applied Biosystems, Darmstadt, Germany). The expression of iPLA 2␤ and iPLA2␥ in rat kidney and mTAL cells was detected by conventional PCR using a forward primer from exon 13 (5=-CCGGCCAATGGACGCTTCT-3=) and a reverse primer from exon 16 (TGGACAAGCTTCTGGAACTC) for iPLA 2␤ and (5=-GAAGGCCGGGCAGGCTGATG-3=) and (5=-AGTCCCTTGGGAGCAGAAGTGC-3=) for iPLA2␥. PCR without the addition of cDNA served as a negative control. TaqMan quantitative RT-PCR for NKCC2 and iPLA2␤ was performed using the Applied Biosystems probes Rn.01485101 for NKCC2 and Rn.01504428 for iPLA2␤ and the 7500 Fast Real-Time PCR system (Applied Biosystems) following the manufacturer's instructions. The mRNA levels of GAPDH were determined in parallel and served as a loading control (catalog no. 4352338E, Applied Biosystems). The probe for iPLA 2␤ was directed against the transition of exons 5 and 6, which is present in all known iPLA2␤ splice variants. Expression levels were calculated according to the 2 Ϫ⌬⌬CT method and expressed as % of control (26) .
Western blot analysis. Samples were homogenized in sucrosetriethanolamine buffer (41) . Nuclei were removed by centrifugation at 800 g for 10 min at 4°C, and supernatant protein concentration was determined by a bicinchoninic acid protein assay reagent kit (Thermo Fisher Scientific, Bonn, Germany). Samples were subsequently separated by SDS-PAGE in a 10% gel (50 g protein/lane) and electrophoretically transferred to nitrocellulose membranes. Equity in protein loading and blotting was verified by membrane staining using 0.1% Ponceau red stain. Nonspecific protein binding sites were blocked by immersion in 5% nonfat dry milk in PBS. Membranes were subsequently incubated with the respective primary antibody. For detection of iPLA2␤, we used an affinity-purified rabbit anti iPLA2␤ antibody (1:500, HPA001171, Sigma-Aldrich). This antibody is directed against amino acids 100 -250 of human iPLA2␤ protein and thus recognizes all described splice variants of the enzyme. The homologies toward the murine and rat proteins are 90 and 91%, respectively. Total NKCC2 protein abundance was evaluated using either a mouse monoclonal antibody against the COOH-terminal part of NKCC1 which cross-reacts with NKCC2 (T4 antibody developed by Lytle and Forbush III; Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA) or a guinea pig anti NKCC2 antibody against the N-terminal part of the protein to detect total NKCC2 (28, 31) . Phosphorylated NKCC2 was detected using a rabbit anti-pNKCC2 antibody as previously described (31) . Membranes were incubated with the primary antibodies for 1 h at room temperature followed by an overnight incubation at 4°C. Bound antibody was detected using the respective horseradish peroxidase-conjugated secondary antibody and chemiluminescence. Developed X-ray films were scanned and densitometrically evaluated using AlphaImager software (Cell Biosciences, Santa Clara, CA). Expression levels were normalized to the expression of the housekeeping gene ␤-actin using a well-characterized monoclonal antibody (1:20 000, Sigma-Aldrich) and expressed as % of control.
Immunostaining. Immunostaining for iPLA 2␤ was performed using rabbit anti-iPLA2␤ antibody in a 1:50 dilution. Identification of iPLA2␤-expressing nephron segments was achieved by double labeling with the segment-specific markers guinea pig anti-thiazide-sensitive Na ϩ -Cl Ϫ cotransporter (NCC; 1:100) for distal convoluted tubule, goat anti-calbindin-D28k (1:1,000) for distal convoluted tubule and connecting tubule, and goat anti-aquaporin-2 (1:100, sc-9882, Santa Cruz Biotechnology, Heidelberg, Germany) for connecting tubule and collecting duct as previously described (31) . Total NKCC2 and pNKCC2 were detected using well-characterized antibodies against the nonphosphorylated (guinea pig anti-NKCC2; 1:500) and the phosphorylated N-terminal part of NKCC2 (rabbit anti-pNKCC2; 1:20,000) as previously described (31) . Nuclei were stained with 4=-6-diamidino-2-phenylindole (DAPI). For all antibodies, control experiments were conducted in which the primary antibody was omitted.
Verification of iPLA 2␤ antibody. Antibody specificity was further verified by peptide blockade. To this end, immunizing peptide was obtained from the antibody manufacturer (Atlas Antibodies, Stockholm, Sweden). iPLA 2␤ antibody was diluted in 5% nonfat dry milk in PBS and incubated for 30 min with different amounts of blocking peptide before application to mouse kidney sections. Immunostaining was performed as described above. For Western blotting, rat total kidney homogenates were separated by SDS-PAGE in a 10% gel and electrophoretically transferred to nitrocellulose membranes as described above. iPLA 2␤ antibody was incubated with a 10-fold excess of blocking peptide for 30 min and added to the membranes. Signal generation was achieved as described above.
Rip-flip immunoelectron microscopy. Preparation of plasma membrane sheets was performed as previously described (42) . Briefly, mTAL cells were grown to confluence on glass coverslips and treated with 5 M (S)-BEL or vehicle as described above. After 1 h, cells were fixed for 15 min using 0.5% PFA in PBS. After fixation, cells were washed multiple times in PBS and subsequently inverted on nickel electron microscopy grids that had been coated with formvar and carbon and, on the day of the experiment, glow-discharged and floated on poly-L-lysine (0.8 mg/ml for 30 min, followed by 10-s rinsing in distilled H 2O and air drying). Pressure was applied to the coverslip for 15 s using a fine pair of forceps. The coverslips were subsequently lifted, leaving sections of the upper cell surface adherent to the poly-L-lysine-coated grid. Membranes were subsequently fixed in 2% PFA for 20 min at room temperature. Labeling of pNKCC2 was performed by sequential incubation with pNKCC2 antibody (1:150) and gold-conjugated secondary antibody (1:50, Abcam, Cambridge, UK); to this end, grids were placed into droplets. Samples were then postfixed in 2% glutaraldehyde in PBS and processed for 10 min in 1% aqueous tannic acid and 10 min with 1% aqueous uranyl acetate separated by washing with dH2O. Grids were air-dried and examined by transmission electron microscope (Zeiss E905, Zeiss, Oberkochen, Germany).
Statistical analysis. All values are given as means Ϯ SE of 4 animals/group. Statistical analysis was performed using an unpaired Student's t-test. A null hypothesis has been excluded when P was Ͻ0.05.
RESULTS

Gene expression analysis of dDAVP effects on TAL PLA 2 isoenzymes.
A comprehensive list of 31 mammalian enzymes with PLA 2 enzyme activity was obtained from a recent review (30) . Nine of these were expressed in the TAL as revealed by the mTAL transcriptome database (43) , and two of the enzymes were significantly altered following AVP treatment. Regulated enzymes included the calcium sensitive PLA 2 group IVA (ϩ98%) and iPLA 2 ␤ (Ϫ23%) ( Table 1) .
Expression of iPLA 2 ␤ in rat kidney and mTAL cells. Analysis of iPLA 2 ␤ mRNA accumulation in SD rat kidney and cultured mTAL cells showed a product of the expected size of 500 bp by conventional PCR (Fig. 1A) . iPLA 2 ␥ mRNA was expressed in both sources as well (data not shown). In Western blot analysis from rat kidney extracts, a dominant iPLA 2 ␤-immunoreactive band at ϳ70 kDa and additional, weaker bands at 84, 63, 52, and 48 kDa were detectable (Fig. 1B) . mTAL cells only showed the 84-, 70-, and 48-kDa bands; here, the 84-and 70-kDa bands were equally abundant (Fig. 1B) . In Fig. 4 . Characterization of iPLA2␤ antibody. Immunofluorescence labeling of mouse kidney sections with rabbit anti-iPLA2␤ antibody (red) and guinea pig anti-NKCC2 antibody (green). Blue signals mark DAPI-stained nuclei. TAL profiles in the outer medulla show coexpression of iPLA2␤ and NKCC2 (A). iPLA2␤ staining was abolished after preincubation of iPLA2␤ antibody with a 10-fold excess of immunizing peptide (B). Immunofluorescence staining; original magnification ϫ400 for A and B. *Marks profiles of TAL, and CD marks profiles of collecting ducts. the kidney cortex, iPLA 2 ␤ signals were weaker than in the medulla; in the outer medulla, the 70-kDa band was dominant, whereas in the inner medulla the 84-kDa variant was stronger (Fig. 1C) .
Localization of iPLA 2 ␤ in kidney and mTAL cells. Distribution of iPLA 2 ␤ was analyzed by immunofluorescence in rodent and human kidney samples and cultured mTAL cells. Strong iPLA 2 ␤ immunoreactivity was found in the distal nephron of all examined species. Cellular staining was distributed throughout the cytoplasm, with some scattered, particulate signals. In the glomeruli, podocytes showed weak but consistent iPLA 2 ␤ immunoreactivity. Proximal tubules and the renal vasculature were devoid of staining. Double labeling with anti-NKCC2 in rat, mouse, and human kidneys revealed that iPLA 2 ␤ was expressed along the entire medullary and cortical TAL with the exception of the macula densa (Fig. 2) . In addition, iPLA 2 ␤ was expressed in distal convoluted and connecting tubules as revealed by coexpression with NCC or calbindin-D 28k (Fig. 3) , respectively. Calbindin-D 28k -negative intercalated cells were also negative for iPLA 2 ␤ (Fig. 3) . In cultured mTAL cells, particulate iPLA 2 ␤ signals of varying strength were found in scattered groups of cells (Fig. 2I) . Double labeling of murine kidney sections with iPLA 2 ␤ and aquaporin-2 demonstrated colocalization of the two products in inner medullary collecting ducts whereas cortical collecting ducts were devoid of immunoreactive iPLA 2 ␤ protein (Fig. 3) .
Characterization of iPLA 2 ␤ antibody. Specificity of the iPLA 2 ␤ antibody was verified by peptide blockade. Preincubation of the iPLA 2 ␤ antibody with iPLA 2 ␤ peptide caused a dose-dependent decrease in signal intensity in immunofluorescence (Fig. 4) and Western blotting (data not shown). Blockade of signal was maximal at a 10-fold excess of peptide (Fig. 4B) .
Effect of chronic dDAVP treatment on NKCC2 and iPLA 2 ␤. To study the effect of a chronic activation of TAL transport on iPLA 2 ␤ expression, Brattleboro rats were treated with the AVP V2 receptor analog dDAVP for 3 days using osmotic minipumps. This resulted in a significant drop in urine flow (Ϫ94 Ϯ 24% compared with controls; P Ͻ 0.05) and a major increase in outer medullary immunoreactive pNKCC2 protein (Fig. 5A) . Analysis of the outer medulla confirmed induction of pNKCC2 abundance (ϩ130 Ϯ 32% compared with controls; Western blotting; P Ͻ 0.05; Fig. 5, B and C) . Total NKCC2 protein and mRNA abundance were increased as well (ϩ130 Ϯ 7% compared with controls; Western blotting; P Ͻ 0.05; Fig. 5 , B and C, and ϩ70 Ϯ 5% compared with controls; real-time PCR; P Ͻ 0.05; Fig. 5D ). These results document an activation of NKCC2 in the TAL of the treated animals, thus confirming previous findings (31) . Concomitantly, immunoreactive levels of the 84-and the 70-kDa variants of iPLA 2 ␤ were diminished (Fig. 6A) . Quantification of the 70-kDa variant revealed a reduction of Ϫ65 Ϯ 7% compared with controls (P Ͻ 0.05; Fig. 6B ). iPLA 2 ␤ mRNA accumulation was reduced as well (Ϫ30 Ϯ 3% compared with controls; P Ͻ 0.05; Fig. 6C ). 1-3) showing increased pNKCC2 signals in the treated cells. E. Densitometric analysis of the blots in D. *P Ͻ 0.05.
F870 iPLA2␤ REGULATES NKCC2
Effect of BEL on NKCC2 phosphorylation. The effect of iPLA 2 on NKCC2 phosphorylation was studied in mTAL cells using the established iPLA 2 inhibitor BEL (5 M, 1 h). This caused a rapid and pronounced increase in the amount of immunoreactive pNKCC2 as determined by immunofluorescence (Fig. 7A ) and Western blotting (ϩ189 Ϯ 6% compared with controls; P Ͻ 0.05; Fig. 7 , B and C). Total NKCC2 levels remained unchanged (Fig. 5, B and C) . BEL-treated mTAL cells revealed increased immunoreactive levels of phospho-NKCC2 (pNKCC2) along the lateral and apical plasma membrane (Fig. 7A) .
Effect of propranolol and MAFP on NKCC2 phosphorylation. High concentrations of BEL have been shown to inhibit PAPH in addition to iPLA 2 (4, 13). To rule out an involvement of PAPH in the regulation of NKCC2, we treated mTAL cells with the PAPH inhibitor propranolol or the nonspecific phospholipase inhibitor MAFP (25) . Treatment of mTAL cells with 100 M MAFP for 1 h increased the abundance of pNKCC2 to a similar extent as BEL (ϩ102 Ϯ 7.5% compared with controls; P Ͻ 0.05; Fig. 7, D and E) . In contrast, propranolol had no effect (data not shown). The effect of BEL on NKCC2 phosphorylation is therefore likely due to inhibition of an iPLA 2 isoenzyme (3, 13, 25) .
Effect of (R)-BEL and (S)-BEL on NKCC2 phosphorylation.
To explore the contributions of the major iPLA 2 isoforms iPLA 2 ␤ and iPLA 2 ␥ to NKCC2 phosphorylation, we utilized the differential inhibitory effects of BEL enantiomeres on iPLA 2 isoforms. Since iPLA 2 ␤ is known to respond to (S)-BEL, whereas iPLA 2 ␥ is preferentially inhibited by (R)-BEL, a resulting significantly larger increase in pNKCC2 signal after (S)-BEL than after (R)-BEL treatment suggested that the isoform involved in the regulation of NKCC2 phosphorylation is iPLA 2 ␤ (Fig. 8) (21) . Increased abundance of pNKCC2 in the apical membrane of (S)-BEL-treated mTAL cells was further specified by immunogold staining of apical membrane sheets (Fig. 9) . Here, pNKCC2 signal was localized to electron-dense protein aggregations in the treated cells, whereas signal was absent in the controls.
Effect of FKGK 11 on NKCC2 phosphorylation. To further test the hypothesis that iPLA 2 ␤ is involved in the regulation of NKCC2 phosphorylation, we made use of FKGK 11, the newly developed specific inhibitor of iPLA 2 ␤ (5). Short-term treatment of mTAL cells with FKGK 11 increased abundance and membrane presentation of pNKCC2 as determined by immunofluorescence (Fig. 10, a and b) . In vivo experiments in rats confirmed the stimulatory effect of the compound on medullary pNKCC2 levels (Fig. 10, c and d) . Together, these data support a functional link between iPLA 2 ␤ and NKCC2.
DISCUSSION
We have shown that iPLA 2 ␤ is localized to the distal nephron, where it acts as an inhibitory regulator of NKCC2 phosphorylation and apical surface expression. AVP-induced activation of NKCC2 was associated with decreased iPLA 2 ␤ abundance, whereas other members of the iPLA 2 family were not affected. We assume that downregulation of iPLA 2 ␤ is part of the mechanism that provides sustained activation of NKCC2 in response to AVP-V2 receptor signaling.
Mammalian cells of various origins express multiple iPLA 2 ␤ isoenzymes as a result of alternative splicing and proteolytic processing (4, 24, 34, 39) . Using a polyclonal antibody against the N-terminal ankyrin-repeats common to all known splice variants of iPLA 2 ␤, we found abundant expression in the kidney of normal rats. Analysis of the zonal distribution of iPLA 2 ␤ demonstrated the highest relative abun- dance of the 70-kDa variant of the enzyme in the outer medulla; this variant was also detected in cultured mTAL cells. Weaker bands at 84, 63, 52, and 48 kDa were further detected in rat outer medulla. This pattern agrees with other reports on mammalian iPLA 2 ␤ protein expression (4, 24, 34, 39) . Our findings on the tubular distribution of iPLA 2 ␤ in mouse, rat, and human kidney along the distal nephron, connecting tubule, and distal collecting duct were novel; macula densa cells were negative for iPLA 2 ␤, but expressed the calcium-dependent PLA 2 group IV along with cyclooxygenase 2, which may provide active prostaglandin synthesis at this particular site of the kidney (29) . Cellular iPLA 2 ␤ signals within granules and along the basolateral membrane were in agreement with reported data (4, 39). Significant iPLA 2 activity has been reported in proximal tubules, with proximal membrane preparations containing iPLA 2 ␤. In our hands, however, proximal tubules were negative, eventually owing to a low abundance of the enzyme in this segment, and iPLA 2 activity in proximal tubules may also reflect contributions by iPLA 2 ␥ and lysophospholipase 1 (22, 33, 44) . Another site of joint iPLA 2 ␤ and iPLA 2 ␥ expression has been reported from podocytes, and iPLA 2 ␥ was implicated in podocyte injury upon complement activation (9) . In our hands, podocytes showed a weak but consistent iPLA 2 ␤ staining as well.
The significant expression of iPLA 2 ␤ along the TAL suggested that the enzyme may interfere with TAL transepithelial NaCl cotransport, consistent with earlier data on BEL-induced inhibition of iPLA 2 ameliorating dopamine-induced reduction of transport in TAL (16) . Here, the nonselective PLA 2 inhibitor MAFP and the more selective iPLA 2 inhibitor BEL showed that iPLA 2 has an inhibitory effect on NKCC2 phosphorylation and surface expression. Since the pNKCC2 level was preferentially increased by S-BEL compared with R-BEL, identity of the iPLA 2 isoform involved in the regulation of NKCC2 activity was likely iPLA 2 ␤. We were aware that BEL and its enantiomers are not specific for iPLA 2 ␤ but also affect other enzymes such as PAPH, which may interfere with eicosanoid synthesis as well (3, 13) . We therefore applied the PAPH inhibitor propranolol but saw no effect on NKCC2 phosphorylation. In aggregate, these data suggest that iPLA 2 ␤ has an inhibitory effect on NKCC2 phosphorylation and surface expression. This conclusion was further supported by our studies with FKGK 11, the newly developed specific inhibitor of iPLA 2 ␤.
Since several studies have shown that maneuvers which increase NKCC2 phosphorylation also raise NKCC2 transport activity, our observation of increased pNKCC2 levels along with enhanced surface expression of the transporter upon inhibition of iPLA 2 ␤ is likely to reflect increased NKCC2 transport activity (14, 15, 31) .
The mechanisms by which iPLA 2 ␤ may regulate TAL transport activity, are not entirely clear. iPLA 2 ␤ catalyzes the hydrolysis of glycerophospholipids at the sn-2 position, thus generating free fatty acid such as arachidonic acid and a 2-lysophospholipid (LPC). These products have either intrinsic biological activity or can be metabolized to other active molecules (7) . Depending on the array of enzymes available, arachidonic acid can be processed to a variety of metabolites such as 20-HETE, EETs, or prostaglandins. All of these have been shown to modulate TAL transepithelial transport (2, 10, 18) . In outer medullary cell suspensions, arachidonic acid was preferentially metabolized to omega-hydroxylated eicosatetraenoic acid metabolites such as 20-HETE (8, 38) . In agreement with this, cytochrome P-450-4A (CYP4A), the enzyme responsible for 20-HETE generation, is expressed in the entire TAL (21), whereas cyclooxygenase 2, the enzyme responsible for prostaglandin synthesis, is restricted to the macula densa and few, scattered TAL cells of the cortex and corticomedullary transition (6, 17, 35, 37) . The observed reduction of outer medullary iPLA 2 ␤ levels in dDAVP-treated DI rats as well as the pharmacologically induced inhibition of iPLA 2 ␤ in mTAL cells are therefore likely to result in a decrease in 20-HETE, which in turn may cause an activation of NKCC2. In line with this assumption, earlier studies have shown an increased capacity for 20-HETE synthesis in outer medullary tissue preparations from DI rats that was reduced by dDAVP treatment (36) .
Another mechanistic aspect may be considered regarding LPC production by iPLA 2 ␤ during lipid hydrolysis, since LPCs may increase membrane fluidity and facilitate the turnover of membrane rafts (32) . We have previously shown that activation of NKCC2 by AVP is associated with its shift into membrane rafts along with enhanced surface expression (41) . In our setting, inhibition of iPLA 2 ␤ therefore may have been instrumental in raising the degree of active, surface-expressed NKCC2 by stabilizing membrane rafts. Since iPLA 2 ␤ is also involved in membrane-recycling processes (10), impaired endocytosis and consequently increased surface expression of NKCC2 may have contributed to our finding. In summary, we have shown that iPLA 2 ␤, a rate-limiting enzyme for eicosanoid synthesis, is expressed in the distal nephron. Inhibition of iPLA 2 ␤ raises the activity of NKCC2 in the TAL. AVP, an established activator of TAL transport, causes downregulation of iPLA 2 ␤. These results suggest a role for iPLA 2 ␤ as a negative regulator of NKCC2 and critical part of a mechanism contributing to salt and water homeostasis.
